169 related articles for article (PubMed ID: 12610520)
1. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.
De Paola F; Ridolfi R; Riccobon A; Flamini E; Barzanti F; Granato AM; Mordenti GL; Medri L; Vitali P; Amadori D
Br J Cancer; 2003 Jan; 88(2):320-6. PubMed ID: 12610520
[TBL] [Abstract][Full Text] [Related]
2. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.
Hishii M; Kurnick JT; Ramirez-Montagut T; Pandolfi F
Clin Exp Immunol; 1999 Jun; 116(3):388-94. PubMed ID: 10361224
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
[TBL] [Abstract][Full Text] [Related]
4. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.
Riccobon A; Gunelli R; Ridolfi R; De Paola F; Flamini E; Fiori M; Saltutti C; Petrini M; Fiammenghi L; Stefanelli M; Granato AM; Cuzzocrea DE; Amadori D
Cancer Invest; 2004; 22(6):871-7. PubMed ID: 15641485
[TBL] [Abstract][Full Text] [Related]
6. Critical role for perforin-, Fas/FasL-, and TNFR1-mediated cytotoxic pathways in down-regulation of antigen-specific T cells during persistent viral infection.
Zhou S; Ou R; Huang L; Moskophidis D
J Virol; 2002 Jan; 76(2):829-40. PubMed ID: 11752172
[TBL] [Abstract][Full Text] [Related]
7. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
Kessler B; Hudrisier D; Schroeter M; Tschopp J; Cerottini JC; Luescher IF
J Immunol; 1998 Dec; 161(12):6939-46. PubMed ID: 9862728
[TBL] [Abstract][Full Text] [Related]
8. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present.
Wang Q; Stanley J; Kudoh S; Myles J; Kolenko V; Yi T; Tubbs R; Bukowski R; Finke J
J Immunol; 1995 Aug; 155(3):1382-92. PubMed ID: 7636203
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
Mansfield PF; Rosenblum MG; Murray JL; Itoh K
Cancer Immunol Immunother; 1991; 33(4):247-54. PubMed ID: 1829394
[TBL] [Abstract][Full Text] [Related]
10. Human small intestinal mucosa harbours a small population of cytolytically active CD8+ alphabeta T lymphocytes.
Melgar S; Bas A; Hammarström S; Hammarström ML
Immunology; 2002 Aug; 106(4):476-85. PubMed ID: 12153510
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease.
Matsuda M; Petersson M; Lenkei R; Taupin JL; Magnusson I; Mellstedt H; Anderson P; Kiessling R
Int J Cancer; 1995 Jun; 61(6):765-72. PubMed ID: 7790109
[TBL] [Abstract][Full Text] [Related]
12. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
13. Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients.
Choi SH; Chung EJ; Whang DY; Lee SS; Jang YS; Kim CW
Cancer Immunol Immunother; 1998 Feb; 45(6):299-305. PubMed ID: 9490199
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
15. Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression.
Pardo J; Buferne M; Martínez-Lorenzo MJ; Naval J; Schmitt-Verhulst AM; Boyer C; Anel A
Int Immunol; 2003 Dec; 15(12):1441-50. PubMed ID: 14645153
[TBL] [Abstract][Full Text] [Related]
16. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
17. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
18. Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.
Monu N; Frey AB
Cancer Res; 2007 Dec; 67(23):11447-54. PubMed ID: 18056473
[TBL] [Abstract][Full Text] [Related]
19. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
Yang S; Haluska FG
J Immunol; 2004 Apr; 172(7):4599-608. PubMed ID: 15034078
[TBL] [Abstract][Full Text] [Related]
20. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E
Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
